AbCellera Biologics Inc. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
AbCellera Biologics Inc. (ABCL) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $423.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2021-05-14
- AbCellera Biologics Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2021-03-31 was $423.00K, a 345.26% increase year-over-year.
- AbCellera Biologics Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2020-03-31 was $95.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month |
|---|---|
| 2021-03-31 | $423.00K 10-Q · filed 2021-05-14 |
| 2020-03-31 | $95.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |